LGND enters the back half of July with a notable reversal: the short squeeze that never quite came is now unwinding, even as analysts scramble to lift targets toward a stock price they've spent months chasing.
The most striking development this week is how sharply short sellers have pulled back. SI has fallen 26% in the past week alone, dropping to roughly 11% of the free float — still elevated, but down from a multi-week peak above 15% that had built through late June and early July. The retreat followed an aggressive build: as noted in the previous week's note, shorts had nearly doubled their position over the prior month. That tide has turned. The ORTEX short score, which peaked above 73 earlier in the month, has slid to 66 — a directional signal that pressure on the name is easing rather than intensifying. Importantly, the borrowing market never signalled a squeeze was imminent. Availability remains generous at around 216% of short interest, well above the year's tightest reading, and cost to borrow has barely moved — holding flat near 0.53% through the entire 30-day window. Shorts were never trapped; they appear to have simply chosen to exit.
Options positioning complicates the otherwise calmer picture. The put/call ratio jumped to 0.73 on Tuesday — more than two standard deviations above its 20-day average of 0.22, which had been running near the 52-week floor. That's a sudden and significant shift toward downside protection, especially given how call-heavy the options flow had been just days prior, when the PCR sat below 0.10 for nearly two consecutive weeks. The spike mirrors a similar one-day jump on June 23, which quickly reverted. Whether this is structural hedging into the August 7 earnings date or a one-session anomaly is the question the next few days will answer.
The Street has finally started closing the gap between targets and price. The prior note flagged that even bullish analysts couldn't keep pace with a stock that had rallied 35% in a month. That's still the core tension — but the catching-up continues. RBC Capital raised its target to $340 this week, up from $262, while BofA lifted to $388 in early July from $266. Stifel's $332 target from last week now trails the current $301 close less dramatically than it did at $319. The consensus mean is now $311, essentially at-the-money. The direction of travel across every analyst action over the past several months has been uniformly upward — no downgrades, no target cuts. Bulls point to the royalty-and-milestone model, the Phase 3 pipeline candidate, and recent acquisitions; bears cite the $700 million convertible financing and dilution risk from the XOMA deal, along with royalty revenues that have been under pressure. The EPS surprise factor score at just 5 out of 100 is a notable weak spot — the company has not been beating estimates, which limits how much runway the Street enthusiasm alone can carry.
On the institutional side, the ownership picture is broadly stable. BlackRock holds nearly 15% and added shares through June; Invesco added more than 230,000 shares in the same period, a meaningful incremental commitment. The insider picture is less encouraging — Ligand's Chief Legal Officer sold approximately $1.5 million of stock on July 1, spread across multiple tranches, and a Director sold nearly $890,000 in mid-June. Neither sale is catastrophic in size, but the pattern of insiders lightening up while analysts raise targets is a contrast worth noting.
The August 7 earnings print is now the clock the whole setup is running against. After the May 7 report, the stock fell nearly 5% on the day and extended those losses through the week. With the stock down 6% from its recent highs but still up 18% over the past month, and with options traders suddenly buying more protection, the question heading into that release is whether the royalty revenue trajectory and progress on the convertible financing story can justify a price that the Street's own upgraded targets have only just reached.
See the live data behind this article on ORTEX.
Open LGND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
